Figure 2 Examples of histopathological validation

Slides:

Advertisements

Similar presentations

Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.

Advertisements

Figure 1 The heterogenous landscape of triple-negative breast cancer

Improved diagnosis, therapy and outcomes for patients with CUP

Figure 2. Histopathologic findings

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Concept of the therapeutic index

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Development of preclinical models for the guidance of precision medicine. Development of preclinical models for the guidance of precision medicine. A,

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of a patients with CUP

Figure 1 CAR-T-cell design

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

4155 primary hepatocellular carcinoma with known diagnosis month/year

Figure 2 The patterns of epithelial-to-mesenchymal

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Supplementary figure1. CK7 CK20 CDX2 DPEP1 Cut off value: 85%

Figure 2 Variations between planned and delivered doses of radiation

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Continuing Adjuvant Tamoxifen to 10 Years

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Empiric versus Site-Directed Chemotherapy in Cancer of Unknown Primary

Esteller, New England Journal of Medicine, 2008

SAF-1 expression in clinical breast cancer tissues.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

Figure 1 Gene-expression quantification methods

PD-L1 is expressed in breast cancer.

Establishment and characterization of primary CAFs from patients with colorectal cancer. Establishment and characterization of primary CAFs from patients.

Presentation transcript:

Figure 2 Examples of histopathological validation of patients with CUP with an EPICUP-predicted tissue of origin Figure 2 | Examples of histopathological validation of patients with CUP with an EPICUP-predicted tissue of origin. a | CUP predicted by EPICUP to be a sarcoma: histopathological validation of the EPICUP-based diagnosis using a tumour sample after autopsy, using haematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) for vimentin, a specific marker for sarcoma, and the non-sarcoma marker S100 (negative). b | CUP predicted by EPICUP to be breast cancer. Diagnosis was confirmed by H&E staining and IHC for cytokeratins CK-7 (positive) and CK-20 (negative), and the specific breast marker mammaglobin-A (positive). c | CUP predicted to be a colon carcinoma by EPICUP, and validated using H&E staining and IHC for CK-7 (negative), CK20 (positive), and the specific colon marker homeobox protein CDX-2 (positive). Moran, S. et al. (2017) Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.97